Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, it develops its engEx Platform to expand upon the innate properties of exosomes to design, engineer, and manufacture exosome therapeutic candidates. Codiak Biosciences utilizes its platform to generate a pipeline of engineered exosomes aimed at treating a range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases.